Market Performance
Despite a broader market downturn, Sudarshan Pharma shares defied the trend on Friday, showing resilience on the BSE. While benchmark indices like the Sensex dropped over 1.4%, Sudarshan Pharma shares stayed firm during intraday trading.
- Opening Price (April 25, 2025): ₹27.80
- Previous Close: ₹27.26
- Intraday Gain: ~2%
- The stock remained locked in the upper circuit, reaching its maximum permissible price limit during the trading session.
Main News
In a remarkable show of investor confidence, Sudarshan Pharma shares have surged 250% over the past year. Thanks to solid quarterly earnings, the strong upward trajectory continues even amid a volatile market environment.
The company announced its Q4 FY2025 results, revealing a robust growth pattern in revenue and profitability.
Company Performance Highlights
Revenue
- Q4 FY2025 Revenue: ₹277.6 crore
- Growth: Up 18.8% from ₹233.76 crore in Q4 FY2024
Net Profits
- Consolidated Net Profit: ₹10.03 crore
- YoY Growth: +52% from ₹6.64 crore
- Standalone Net Profit: ₹9.95 crore
- YoY Growth: +54% from ₹6.46 crore
These numbers underline the company’s firm financial footing and consistent performance.
Sudarshan Pharma Shares: A Multibagger in Focus
The 250% rally over the past 12 months puts Sudarshan Pharma shares in the spotlight as one of the top-performing pharma stocks on the BSE. Despite recent market weakness, this stellar growth has come, underscoring investor trust in the company’s fundamentals.
Summary
- Sudarshan Pharma shares have delivered 250% returns in one year.
- Despite a steep market crash on April 25, 2025, the stock surged to its upper circuit limit.
- Q4 FY2025 financials showed substantial revenue and profit growth:
- Revenue: ₹277.6 crore (+18.8% YoY)
- Net Profit: ₹10.03 crore (+52% YoY)
With this kind of financial momentum and market resilience, Sudarshan Pharma shares remain a stock to watch in the pharmaceutical segment.
